Delisting of goserelin 3.6 mg implant (Zoladex Implant™) from the Pharmaceutical Benefits Scheme – 1 November 2026
Page last updated: 13 May 2026
Goserelin 3.6 mg implant (Zoladex Implant™) will be delisted from the Pharmaceutical Benefits Scheme (PBS) on 1 November 2026 at the request of AstraZeneca Pty Ltd (AstraZeneca).
AstraZeneca has chosen to remove the medicine from the PBS for commercial reasons. AstraZeneca has also stated that the product will no longer be available to patients with non-PBS (private) prescriptions. The Department of Health, Disability and Ageing has attempted to retain the listing on the PBS. However, sponsors are private entities that make their own decisions regarding their medicines and cannot be compelled by the Government to continue to list a product on the PBS.
The Australian Government appreciates that it is important for Australians to have access to the medicines they need. The Government relies on the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) about the removal of medicines from the PBS. The PBAC has advised that the delisting of this product will result in unmet clinical need.
Alternative options remain listed on the PBS, including goserelin 10.8 mg implant (Zoladex 10.8 Implant™) and other gonadotropin-releasing hormone (GnRH) agonists for the prostate cancer and endometriosis indications. However, it is recognised that there are currently no other PBS listed options for hormone receptor positive breast cancer and anticipated premature ovarian failure.
AstraZeneca has advised its stakeholders that it is preparing an application to seek government regulatory and PBS reimbursement approvals to expand the indication for the Zoladex 10.8mg implant to include breast cancer patients that are hormone receptor positive. Any such applications would be considered through the usual Therapeutic Goods Administration and PBAC process.
Alternative options for GnRH agonists for anticipated premature ovarian failure are also being investigated.
All patients using the goserelin 3.6 mg implant are encouraged to discuss its forthcoming discontinuation with their treating practitioner.
If you have any questions regarding the rationale for this delisting, whether there are plans to relist the item, or to discuss any alternative pathways to access the medicine, please contact AstraZeneca directly on 1800 805 342 or via https://contactazmedical.astrazeneca.com.
If you have any questions regarding the delisting process, please contact Rebecca Richardson, Assistant Secretary, PBS Listing, Pricing and Policy Branch, at pbslisting@health.gov.au.
The department will continue to provide updates to affected stakeholders as they become available.
